Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Small Cell Lung Carcinoma 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Optic Nerve Glioma 3Oligodendroglioma 3Leukemia, Myeloid, Acute 3Leukemia 3Central Nervous System Neoplasms 3Astrocytoma 3Sarcoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2Familial ependymoma 2Drug-Related Side Effects and Adverse Reactions 2Burkitt Lymphoma 2Breast Neoplasms 2Wilms Tumor 1Thrombocytopenia 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1

Interventions

Cisplatin 3Pemetrexed 2Etoposide 2pomalidomide 1etoposide phosphate 1enzalutamide 1bemiparin 1apalutamide 1alvocidib 1abiraterone 1Radiation 1RRx-001 1Gemcitabine 1GSK2879552 1Depsipeptides 1Carboplatin 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Small Cell × etoposide phosphate × Clear all
NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Celgene

Phase 1/2 Terminated
22 enrolled 13 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡